Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 93

1.

Transarterial chemoembolization for hepatocellular carcinoma: development and external validation of the Munich-TACE score.

Op den Winkel M, Nagel D, Op den Winkel P, Trojan J, Paprottka PM, Steib CJ, Schmidt L, Göller M, Stieber P, Göhring P, Herbst A, Rentsch M, De Toni EN, Göke B, Gerbes AL, Kolligs FT.

Eur J Gastroenterol Hepatol. 2018 Jan;30(1):44-53. doi: 10.1097/MEG.0000000000001005.

PMID:
29076939
2.

Methylated free-circulating HPP1 DNA is an early response marker in patients with metastatic colorectal cancer.

Herbst A, Vdovin N, Gacesa S, Ofner A, Philipp A, Nagel D, Holdt LM, Op den Winkel M, Heinemann V, Stieber P, Graeven U, Reinacher-Schick A, Arnold D, Ricard I, Mansmann U, Hegewisch-Becker S, Kolligs FT.

Int J Cancer. 2017 May 1;140(9):2134-2144. doi: 10.1002/ijc.30625. Epub 2017 Feb 22. Erratum in: Int J Cancer. 2018 Feb 1;142(3):E1.

3.

Tumor markers in the early detection of tumor recurrence in breast cancer patients: CA 125, CYFRA 21-1, HER2 shed antigen, LDH and CRP in combination with CEA and CA 15-3.

Di Gioia D, Blankenburg I, Nagel D, Heinemann V, Stieber P.

Clin Chim Acta. 2016 Oct 1;461:1-7. doi: 10.1016/j.cca.2016.07.014. Epub 2016 Jul 22.

PMID:
27451906
4.

Diagnostic efficacy of CA 15-3 and CEA in the early detection of metastatic breast cancer-A retrospective analysis of kinetics on 743 breast cancer patients.

Stieber P, Nagel D, Blankenburg I, Heinemann V, Untch M, Bauerfeind I, Di Gioia D.

Clin Chim Acta. 2015 Aug 25;448:228-31. doi: 10.1016/j.cca.2015.06.022. Epub 2015 Jul 6.

PMID:
26160053
5.

Preoperative serum markers for individual patient prognosis in stage I-III colon cancer.

Giessen-Jung C, Nagel D, Glas M, Spelsberg F, Lau-Werner U, Modest DP, Schulz C, Heinemann V, Di Gioia D, Stieber P.

Tumour Biol. 2015 Sep;36(10):7897-906. doi: 10.1007/s13277-015-3522-z. Epub 2015 May 8.

PMID:
25953265
6.

Serum HER2 in combination with CA 15-3 as a parameter for prognosis in patients with early breast cancer.

Di Gioia D, Dresse M, Mayr D, Nagel D, Heinemann V, Stieber P.

Clin Chim Acta. 2015 Feb 2;440:16-22. doi: 10.1016/j.cca.2014.11.001. Epub 2014 Nov 7.

PMID:
25444743
7.

Evaluation of preoperative serum markers for individual patient prognosis in stage I-III rectal cancer.

Giessen C, Nagel D, Glas M, Spelsberg F, Lau-Werner U, Modest DP, Michl M, Heinemann V, Stieber P, Schulz C.

Tumour Biol. 2014 Oct;35(10):10237-48. doi: 10.1007/s13277-014-2338-6. Epub 2014 Jul 17.

PMID:
25027407
8.

Circulating cell-free methylated DNA and lactate dehydrogenase release in colorectal cancer.

Philipp AB, Nagel D, Stieber P, Lamerz R, Thalhammer I, Herbst A, Kolligs FT.

BMC Cancer. 2014 Apr 8;14:245. doi: 10.1186/1471-2407-14-245.

9.

Serum HER2 supports HER2-testing in tissue at the time of primary diagnosis of breast cancer.

Di Gioia D, Dresse M, Mayr D, Nagel D, Heinemann V, Kahlert S, Stieber P.

Clin Chim Acta. 2014 Mar 20;430:86-91. doi: 10.1016/j.cca.2013.12.036. Epub 2014 Jan 9.

PMID:
24412321
10.

Circulating nucleosomes and immunogenic cell death markers HMGB1, sRAGE and DNAse in patients with advanced pancreatic cancer undergoing chemotherapy.

Wittwer C, Boeck S, Heinemann V, Haas M, Stieber P, Nagel D, Holdenrieder S.

Int J Cancer. 2013 Dec 1;133(11):2619-30. doi: 10.1002/ijc.28294. Epub 2013 Aug 9.

11.

Magnetic resonance colonography for the detection of colorectal neoplasia in asymptomatic adults.

Graser A, Melzer A, Lindner E, Nagel D, Herrmann K, Stieber P, Schirra J, Mansmann U, Reiser MF, Göke B, Kolligs FT.

Gastroenterology. 2013 Apr;144(4):743-750.e2. doi: 10.1053/j.gastro.2012.12.041. Epub 2013 Feb 13.

PMID:
23415805
12.

DNase is a prognostic marker in liver cancer patients receiving transarterial chemoembolization therapy.

Kohles N, Nagel D, Jüngst D, Stieber P, Holdenrieder S.

Int J Clin Pharmacol Ther. 2013 Jan;51(1):80-3. No abstract available.

13.

Soluble receptor of advanced glycation end products (sRAGE) indicates response to chemotherapy in pancreatic cancer patients.

Wittwer C, Boeck S, Heinemann V, Haas M, Stieber P, Nagel D, Holdenrieder S.

Int J Clin Pharmacol Ther. 2013 Jan;51(1):67-9. No abstract available.

14.

CA 15-3 is a predictive and prognostic biomarker in patients with metastasized breast cancer undergoing Selective Internal Radiation Therapy.

Fahmueller YN, Nagel D, Hoffmann RT, Tatsch K, Jakobs T, Stieber P, Holdenrieder S.

Int J Clin Pharmacol Ther. 2013 Jan;51(1):63-6. No abstract available.

15.

Human epididymis protein 4 (HE4) in benign and malignant diseases.

Hertlein L, Stieber P, Kirschenhofer A, Krocker K, Nagel D, Lenhard M, Burges A.

Clin Chem Lab Med. 2012 Dec;50(12):2181-8.

PMID:
23093276
16.

Prognosis of patients with hepatocellular carcinoma. Validation and ranking of established staging-systems in a large western HCC-cohort.

op den Winkel M, Nagel D, Sappl J, op den Winkel P, Lamerz R, Zech CJ, Straub G, Nickel T, Rentsch M, Stieber P, Göke B, Kolligs FT.

PLoS One. 2012;7(10):e45066. doi: 10.1371/journal.pone.0045066. Epub 2012 Oct 5.

17.

Immunogenic cell death biomarkers HMGB1, RAGE, and DNAse indicate response to radioembolization therapy and prognosis in colorectal cancer patients.

Fahmueller YN, Nagel D, Hoffmann RT, Tatsch K, Jakobs T, Stieber P, Holdenrieder S.

Int J Cancer. 2013 May 15;132(10):2349-58. doi: 10.1002/ijc.27894. Epub 2013 Jan 18.

18.

Predictive value of immunogenic cell death biomarkers HMGB1, sRAGE, and DNase in liver cancer patients receiving transarterial chemoembolization therapy.

Kohles N, Nagel D, Jüngst D, Stieber P, Holdenrieder S.

Tumour Biol. 2012 Dec;33(6):2401-9. doi: 10.1007/s13277-012-0504-2. Epub 2012 Sep 11.

PMID:
22965881
19.

Anthracycline-induced cardiotoxicity: cardiac monitoring by continuous wave-Doppler ultrasound cardiac output monitoring and correlation to echocardiography.

Geiger S, Stemmler HJ, Suhl P, Stieber P, Lange V, Baur D, Hausmann A, Tischer J, Horster S.

Onkologie. 2012;35(5):241-6. doi: 10.1159/000338335. Epub 2012 Apr 23.

PMID:
22868502
20.

Nature and dynamics of nucleosome release from neoplastic and non-neoplastic cells.

Holdenrieder S, Kolligs FT, Braess J, Manukyan D, Stieber P.

Anticancer Res. 2012 May;32(5):2179-83.

PMID:
22593507

Supplemental Content

Loading ...
Support Center